Lung Stent Market Size & Share 2025 – 2034

Lung Stent Market Size

The global lung stent market size was valued at USD 161.7 million in 2024 and is expected to exhibit growth at a CAGR of 9.3% from 2025 to 2034. The high market growth can be attributed to the rising prevalence of COPD, growing emphasis on minimally invasive surgeries, and increasing investments in the development of technologically advanced products.

The market is growing rapidly due to the rising global prevalence of chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. Contributing factors include heightened exposure to air pollution, widespread smoking habits, and the adoption of sedentary lifestyles, all of which have led to a significant rise in respiratory disorders. This has created a pressing need for effective therapeutic solutions, with lung stent emerging as a critical intervention. Moreover, the aging population, which is more susceptible to airway complications, is further fueling the demand for these devices.
 

Technological advancements in stent materials and designs are significantly driving the growth of the lung stent market. Cutting-edge innovations, such as drug-eluting stents, biodegradable stents, and hybrid models, are gaining traction for their superior efficacy in minimizing complications and enhancing patient outcomes. These advancements align with the growing adoption of minimally invasive procedures, which have transformed the treatment landscape by offering reduced recovery times, lower complication rates, and improved overall patient experiences.
 

Lung stent, or airway stents, are tubular medical devices designed to maintain patency in the trachea or bronchi, which may become obstructed due to tumors, infections, or trauma. These stents are crafted from materials like silicone, metal, or hybrids and are widely used in conditions such as lung cancer, tracheomalacia, and COPD. Available in self-expandable and balloon-expandable configurations, lung stent is crucial in restoring airflow and alleviating respiratory distress.

Lung Stent Market Trends

The market is being shaped by several emerging trends, including the increasing use of 3D printing technology for creating patient-specific stents. This innovation allows for personalized solutions tailored to complex airway anatomies, improving procedural outcomes. Biodegradable stents are also gaining traction as they eliminate the long-term risks associated with permanent implants, such as infections or migration.
 

• Artificial intelligence (AI) and machine learning (ML) are revolutionizing procedural planning and diagnostic accuracy in the market. AI-powered imaging systems enhance precision in stent placement, reducing procedural errors and improving patient outcomes. Furthermore, the integration of digital health platforms is enabling remote patient monitoring, offering timely interventions and follow-ups post-procedure.
   
• The market is also witnessing collaborations between medical device companies and research institutions to develop next-generation lung stent. These partnerships focus on enhancing durability, flexibility, and biocompatibility. Growing investment in emerging economies, driven by the increasing availability of healthcare infrastructure, is further contributing to market growth. These trends collectively point to a future of innovation and expanded accessibility in the market.
   

Lung Stent Market Analysis

Based on product, the market is classified into tracheal stents, bronchial stents, and laryngeal stents. The tracheal stents segment generated the highest revenue of USD 111.9 million in 2024.
 

• Tracheal stents hold a major market share due to their widespread application in managing tracheal obstructions caused by tumors, infections, or congenital abnormalities. These stents are often preferred in severe airway blockages, offering a life-saving solution for patients with compromised breathing. Their ability to provide immediate relief and maintain airway patency has given them a standard of care in various emergency and planned procedures.
   
• Moreover, the high adoption of tracheal stents is also attributed to their versatility and availability in a range of materials and designs, catering to specific patient needs. Silicone tracheal stents, for instance, are widely favored for their cost-effectiveness and biocompatibility, while hybrid and metal stents provide enhanced durability and customization.
   

Based on device type, the lung stent market is classified into self-expandable and balloon expandable. The self-expandable segment accounted for USD 126.5 million market revenue in 2024 and is anticipated to grow at a CAGR of 9.4% between 2025 to 2034 period.
 

• Self-expandable stents dominate the market due to their ease of deployment and adaptability to complex airway anatomies. These stents are engineered to expand automatically upon placement, minimizing procedural time and ensuring precise positioning. Self-expandable stents are particularly advantageous in emergency cases, where quick airway restoration is critical to patient survival. Their flexible structure allows for better conformity to the airway, reducing the risk of tissue damage or complications such as perforations. This feature makes them a preferred choice for treating conditions like tracheomalacia and severe airway obstructions.
   
• In addition, the growing demand for minimally invasive procedures has further propelled the adoption of self-expandable stents. These stents are compatible with advanced imaging techniques, facilitating accurate placement and reducing the need for repeat interventions. Further, their superior biocompatibility and ability to adapt to dynamic airway movements make them a sustainable option for long-term use. Manufacturers are focusing on incorporating anti-migration features and drug-eluting technologies in self-expandable stents, addressing common challenges and improving patient outcomes.
   

Based on material, the market is segmented into silicone, metal, and hybrid. The silicone segment dominated the market in 2024 and is anticipated to reach USD 217.6 million by the end of the forecast period.
 

• Silicone stents hold a major market share in the lung stent market due to their cost-effectiveness and biocompatibility. These stents are preferred for managing airway obstructions caused by benign conditions, such as tracheal stenosis or post-intubation injuries, due to their inert nature and reduced risk of inflammation. Silicone stents can be easily removed, making them suitable for temporary placements or situations where repeated interventions are anticipated.
   
• Furthermore, the durability of silicone stents and their resistance to migration contribute to their widespread adoption. They are available in various sizes and shapes, ensuring compatibility with diverse airway anatomies. Silicone stents are commonly used in regions with constrained healthcare budgets due to their affordability and proven efficacy.
   

Based on patient, the market is segmented into adult and paediatric. The adult segment dominated the market in 2024 and is anticipated to reach USD 261.8 million by the end of the forecast period.
 

• The adult segment accounts for a significant market share in the lung stent market due to the high prevalence of airway obstructions and respiratory diseases among adults. Conditions such as lung cancer, COPD, and tracheal stenosis are more commonly diagnosed in this demographic, driving the demand for lung stent. Lifestyle factors like smoking, occupational hazards, and prolonged exposure to air pollution are major contributors to respiratory disorders among adults, making them the largest patient group requiring stent placement.
   
• Moreover, the availability of advanced diagnostic and therapeutic techniques tailored for adult patients facilitates the adoption of lung stent. Healthcare providers are increasingly focusing on minimally invasive treatments for adults, ensuring faster recovery and improved quality of life. Adult patients benefit from a wide range of stent options, including customized designs and materials, allowing for precise treatment of complex airway conditions.
   

Based on end use, the market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 261 million by the end of the forecast period.
 

• Hospitals dominate the lung stent market due to their advanced infrastructure and access to skilled medical professionals. As primary healthcare providers for complex airway obstruction cases, hospitals are well-equipped to perform both emergency and planned stent placements. The availability of state-of-the-art imaging technologies, such as CT scans and bronchoscopy, ensures accurate diagnosis and precise placement of stents.
   
• Hospitals also benefit from higher patient footfall, especially in regions with well-developed healthcare systems. The ability to provide comprehensive pre- and post-procedural care ensures better patient outcomes, further driving the adoption of lung stent in this setting. Hospitals often collaborate with medical device manufacturers to trial innovative stent designs and materials, enabling access to cutting-edge solutions. These collaborations, along with the growing emphasis on minimally invasive treatments, reinforce hospitals leading role in the market.
   

U.S. lung stent market accounted for USD 63.6 million market revenue in 2024 and is anticipated to grow at a CAGR of 8.8% between 2025 to 2034 period.
 

• The U.S. dominates the market due to its robust healthcare system and high incidence of lung cancer and COPD. Favorable reimbursement policies and government initiatives promoting minimally invasive procedures have bolstered market growth. For instance, the National Cancer Institute funding for lung cancer research has indirectly supported the adoption of airway stents for palliative care.
   
• Technological advancements, such as the integration of AI for precise stent placement, have enhanced treatment outcomes. Leading companies based in the U.S. consistently launch innovative products, such as drug-eluting stents, to address clinical challenges. These factors collectively position the U.S. as a major contributor to the market.
   

UK lung stent market is projected to grow remarkably in the coming years.
 

• The UK market benefits from a growing focus on respiratory disease management and improved healthcare policies. The National Health Service (NHS) actively supports the adoption of advanced medical devices, including lung stents, through reimbursement and funding programs. The rising prevalence of lung cancer and smoking-related conditions has fueled demand for tracheal and bronchial stents in the country.
   
• Moreover, the UK emphasizes minimally invasive treatments, supported by extensive training programs for healthcare professionals. Collaborations between medical device companies and research institutions, such as partnerships with universities, have led to innovations tailored for the UK population. These initiatives contribute to the market steady growth.
   

China holds a dominant position in the Asia Pacific lung stent market.
 

• China market is expanding rapidly due to the country’s high smoking rates and increasing cases of respiratory diseases. The large population base and rising awareness of healthcare services have driven demand for airway stents. Domestic manufacturers, such as Micro-Tech (Nanjing), are gaining prominence by offering cost-effective stent solutions tailored to local needs.
   
• The Chinese government focus on improving healthcare infrastructure, particularly in rural areas, has further boosted market adoption. Medical tourism is also a growing factor, with patients from neighboring countries seeking advanced treatments in China. These developments position China as a lucrative market for lung stent in the Asia-Pacific region.
   

Lung Stent Market Share

Industry players are focusing on product launches, mergers, and acquisitions to strengthen their position in the market. Companies like Boston Scientific and Cook Medical are investing in research to introduce advanced stent designs, while others are exploring strategic collaborations. For instance, partnerships with healthcare providers aim to expand access to innovative stent technologies in underserved regions, driving competitive growth.
 

Lung Stent Market Companies

Prominent players operating in the lung stent industry include:

• Boston Medical Products
• Boston Scientific
• HEALTH MICROPORT MEDICAL
• COOK GROUP
• EFER ENDOSCOPY
• HOOD LABORATORIES
• mi-TECH
• MERIT MEDICAL
• MICRO-TECH ENDOSCOPY
• NOVATECH
• STENING
• TaeWoong MEDICAL
• Teleflex
   

Lung Stent Industry News:

• In August 2024, Renata Medical received FDA approval for its Minima Growth Stent, the first device tailored for neonates, infants, and young children with congenital heart defects. Designed to treat aortic coarctation and pulmonary artery stenosis, the stent can expand as children grow, addressing a long-standing need in pediatric cardiology.
   

The lung stent market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Tracheal stents
• Bronchial stents
• Laryngeal stents

Market, By Device Type

• Self-expandable
• Balloon-expandable

Market, By Material

• Silicone
• Metal
  • Stainless steel
  • Nitinol
• Hybrid

Market, By Patient

• Adult
• Pediatric

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE